174 related articles for article (PubMed ID: 18095745)
1. Data resources for investigating drug exposure during pregnancy and associated outcomes: the General Practice Research Database (GPRD) as an alternative to pregnancy registries.
Charlton RA; Cunnington MC; de Vries CS; Weil JG
Drug Saf; 2008; 31(1):39-51. PubMed ID: 18095745
[TBL] [Abstract][Full Text] [Related]
2. Comparing the General Practice Research Database and the UK Epilepsy and Pregnancy Register as tools for postmarketing teratogen surveillance: anticonvulsants and the risk of major congenital malformations.
Charlton RA; Weil JG; Cunnington MC; Ray S; de Vries CS
Drug Saf; 2011 Feb; 34(2):157-71. PubMed ID: 21247222
[TBL] [Abstract][Full Text] [Related]
3. Identifying major congenital malformations in the UK General Practice Research Database (GPRD): a study reporting on the sensitivity and added value of photocopied medical records and free text in the GPRD.
Charlton RA; Weil JG; Cunnington MC; de Vries CS
Drug Saf; 2010 Sep; 33(9):741-50. PubMed ID: 20701407
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the General Practice Research Database congenital heart defects prevalence: comparison to United Kingdom national systems.
Wurst KE; Ephross SA; Loehr J; Clark DW; Guess HA
Birth Defects Res A Clin Mol Teratol; 2007 Apr; 79(4):309-16. PubMed ID: 17286297
[TBL] [Abstract][Full Text] [Related]
5. Monitoring outcomes of pregnancy following drug exposure: a company-based pregnancy registry program.
Shields KE; Wiholm BE; Hostelley LS; Striano LF; Arena SR; Sharrar RG
Drug Saf; 2004; 27(6):353-67. PubMed ID: 15144230
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of selected characteristics of pregnancy drug registries.
Honein MA; Paulozzi LJ; Cragan JD; Correa A
Teratology; 1999 Dec; 60(6):356-64. PubMed ID: 10590397
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy exposure registries.
Kennedy DL; Uhl K; Kweder SL
Drug Saf; 2004; 27(4):215-28. PubMed ID: 15003034
[TBL] [Abstract][Full Text] [Related]
8. Common teratogenic medication exposures-a population-based study of pregnancies in the United States.
Wang Y; Smolinski NE; Thai TN; Sarayani A; Ewig C; Rasmussen SA; Winterstein AG
Am J Obstet Gynecol MFM; 2024 Jan; 6(1):101245. PubMed ID: 38061552
[TBL] [Abstract][Full Text] [Related]
9. Prospective drug safety monitoring using the UK primary-care General Practice Research Database: theoretical framework, feasibility analysis and extrapolation to future scenarios.
Johansson S; Wallander MA; de Abajo FJ; García Rodríguez LA
Drug Saf; 2010 Mar; 33(3):223-32. PubMed ID: 20158286
[TBL] [Abstract][Full Text] [Related]
10. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry.
Ephross SA; Sinclair SM
Headache; 2014; 54(7):1158-72. PubMed ID: 24805878
[TBL] [Abstract][Full Text] [Related]
11. Better data needed from pregnancy registries.
Briggs GG; Polifka J;
Birth Defects Res A Clin Mol Teratol; 2009 Feb; 85(2):109-11. PubMed ID: 19107958
[TBL] [Abstract][Full Text] [Related]
12. Patient Registries: An Underused Resource for Medicines Evaluation : Operational proposals for increasing the use of patient registries in regulatory assessments.
McGettigan P; Alonso Olmo C; Plueschke K; Castillon M; Nogueras Zondag D; Bahri P; Kurz X; Mol PGM
Drug Saf; 2019 Nov; 42(11):1343-1351. PubMed ID: 31302896
[TBL] [Abstract][Full Text] [Related]
13. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment.
Reiff-Eldridge R; Heffner CR; Ephross SA; Tennis PS; White AD; Andrews EB
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):159-63. PubMed ID: 10649172
[TBL] [Abstract][Full Text] [Related]
14. Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study.
Yusuf A; Chia V; Xue F; Mikol DD; Bollinger L; Cangialose C
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1309-1315. PubMed ID: 30240072
[TBL] [Abstract][Full Text] [Related]
15. The safety of sumatriptan and naratriptan in pregnancy: what have we learned?
Cunnington M; Ephross S; Churchill P
Headache; 2009; 49(10):1414-22. PubMed ID: 19804390
[TBL] [Abstract][Full Text] [Related]
16. Cancer recording and mortality in the General Practice Research Database and linked cancer registries.
Boggon R; van Staa TP; Chapman M; Gallagher AM; Hammad TA; Richards MA
Pharmacoepidemiol Drug Saf; 2013 Feb; 22(2):168-75. PubMed ID: 23239282
[TBL] [Abstract][Full Text] [Related]
17. Improving Information on Maternal Medication Use by Linking Prescription Data to Congenital Anomaly Registers: A EUROmediCAT Study.
de Jonge L; Garne E; Gini R; Jordan SE; Klungsoyr K; Loane M; Neville AJ; Pierini A; Puccini A; Thayer DS; Tucker D; Vinkel Hansen A; Bakker MK
Drug Saf; 2015 Nov; 38(11):1083-93. PubMed ID: 26153398
[TBL] [Abstract][Full Text] [Related]
18. Implications of the problem orientated medical record (POMR) for research using electronic GP databases: a comparison of the Doctors Independent Network Database (DIN) and the General Practice Research Database (GPRD).
Carey IM; Cook DG; De Wilde S; Bremner SA; Richards N; Caine S; Strachan DP; Hilton SR
BMC Fam Pract; 2003 Sep; 4():14. PubMed ID: 14516473
[TBL] [Abstract][Full Text] [Related]
19. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
[TBL] [Abstract][Full Text] [Related]
20. The identification of pregnancies within the general practice research database.
Devine S; West S; Andrews E; Tennis P; Hammad TA; Eaton S; Thorp J; Olshan A
Pharmacoepidemiol Drug Saf; 2010 Jan; 19(1):45-50. PubMed ID: 19823973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
